Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform.
CD8+ T cells
HNSCC (head and neck squamous cell carcinoma)
HPV – human papillomavirus
LCMV (lymphocytic choriomeningitis virus)
Pichinde virus (PICV)
active immunization
arenavirus
cancer immunotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
06
2021
accepted:
16
09
2021
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
2
11
2021
Statut:
epublish
Résumé
Engineered viral vectors represent a promising strategy to trigger antigen-specific antitumor T cell responses. Arenaviruses have been widely studied because of their ability to elicit potent and protective T cell responses. Here, we provide an overview of a novel intravenously administered, replication-competent, non-lytic arenavirus-based vector technology that delivers tumor antigens to induce antigen-specific anti-cancer T cell responses. Preclinical studies in mice and cell culture experiments with human peripheral blood mononuclear cells demonstrate that arenavirus vectors preferentially infect antigen-presenting cells. This, in conjunction with a non-lytic functional activation of the infected antigen-presenting cells, leads to a robust antigen-specific CD8
Identifiants
pubmed: 34722273
doi: 10.3389/fonc.2021.732166
pmc: PMC8551556
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
732166Informations de copyright
Copyright © 2021 Lauterbach, Schmidt, Katchar, Qing, Iacobucci, Hwang, Schlienger, Berka, Raguz, Ahmadi-Erber, Schippers, Stemeseder, Pinschewer, Matushansky and Orlinger.
Déclaration de conflit d'intérêts
Author HL, SS, KK, XQ, AH, KS, UB, JR, SA-E, TS, FS, IM and KKO are employees of Hookipa and own stock. CI is an employee of Hookipa who received travel funds and owns stock. DP owns stock in Hookipa and received funding from Hookipa for scientific consultancy, travel funds, writing support, and patent licensing fees. The authors declare that this study received funding from Hookipa Pharma Inc. The funder had the following involvement with the study: study design, collection, analysis, interpretation of data, the writing of this article and the decision to submit it for publication.
Références
Cancer Immunol Immunother. 2017 Feb;66(2):203-213
pubmed: 27052572
Sci Transl Med. 2012 Jan 4;4(115):115ra1
pubmed: 22218690
J Immunol. 2005 Feb 15;174(4):1851-61
pubmed: 15699111
Infect Immun. 1974 May;9(5):821-3
pubmed: 4856825
Virology. 2011 Mar 15;411(2):170-9
pubmed: 21185048
Immunology. 2015 Oct;146(2):312-26
pubmed: 26173587
Vaccines (Basel). 2019 Apr 24;7(2):
pubmed: 31022829
J Clin Invest. 2015 Sep;125(9):3401-12
pubmed: 26214521
Oncoimmunology. 2017 Aug 9;6(11):e1356148
pubmed: 29147608
CMAJ. 2005 Oct 25;173(9):1033
pubmed: 16247097
J Virol. 2015 Dec 16;90(5):2551-60
pubmed: 26676795
HNO. 2020 Feb;68(2):80-86
pubmed: 31915881
J Clin Invest. 2012 Nov;122(11):4037-47
pubmed: 23041628
PLoS Pathog. 2015 Nov 20;11(11):e1005276
pubmed: 26587982
Oral Oncol. 2016 Oct;61:159-65
pubmed: 27553942
Clin Transl Immunology. 2016 Apr 29;5(4):e74
pubmed: 27195117
Microbiology (Reading). 2013 Jan;159(Pt 1):1-11
pubmed: 23175507
Nat Med. 2010 Mar;16(3):339-45
pubmed: 20139992
Curr Gene Ther. 2011 Aug;11(4):307-20
pubmed: 21453277
Clin Cancer Res. 2016 Nov 15;22(22):5487-5496
pubmed: 27185375
Lancet. 2008 Nov 29;372(9653):1894-1905
pubmed: 19012957
Clin Oncol. 1975 Jun;1(2):157-69
pubmed: 1183104
Clin Dev Immunol. 2010;2010:236378
pubmed: 21234340
J Immunol. 2010 Aug 15;185(4):2182-90
pubmed: 20639484
J Infect Dis. 2020 Apr 21;:
pubmed: 32313928
Semin Immunol. 2020 Aug;50:101430
pubmed: 33262065
Clin Cancer Res. 2020 Apr 15;26(8):1953-1964
pubmed: 31964784
J Virol. 2015 Dec;89(24):12513-7
pubmed: 26423945
Immunity. 2006 Jul;25(1):153-62
pubmed: 16860764
Nat Med. 2014 Oct;20(10):1126-9
pubmed: 25194571
Oncoimmunology. 2020 Sep 15;9(1):1809960
pubmed: 33457095
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3473-8
pubmed: 19208813
J Virol. 2011 Nov;85(22):11770-80
pubmed: 21900169
Immunol Res. 2002;26(1-3):309-21
pubmed: 12403369
Crit Rev Oncol Hematol. 2020 Sep;153:102984
pubmed: 32569853
Cell Rep Med. 2021 Mar 03;2(3):100209
pubmed: 33763654
Sci Transl Med. 2014 Mar 5;6(226):226ra32
pubmed: 24598590
Immunity. 1998 Feb;8(2):177-87
pubmed: 9491999
Ann N Y Acad Sci. 2009 Sep;1171 Suppl 1:E65-74
pubmed: 19751405
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Nat Immunol. 2003 Dec;4(12):1191-8
pubmed: 14625547
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
Sci Transl Med. 2012 Jan 4;4(115):115ra2
pubmed: 22218691
Br J Cancer. 2015 Sep 15;113(6):886-93
pubmed: 26313665
Curr Top Microbiol Immunol. 2002;263:1-5
pubmed: 11987811
Science. 2012 Feb 24;335(6071):984-9
pubmed: 22323740
Hum Vaccin Immunother. 2014;10(11):3332-46
pubmed: 25483639
Curr Top Microbiol Immunol. 2002;263:V-XII
pubmed: 11987823
Nat Immunol. 2021 Aug;22(8):1042-1051
pubmed: 34267375
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Immunotargets Ther. 2020 Oct 07;9:167-200
pubmed: 33117742
Viruses. 2019 Oct 09;11(10):
pubmed: 31600915
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):7320-7325
pubmed: 29941589
Head Neck. 2019 Oct;41 Suppl 1:4-18
pubmed: 31573752
Curr Top Microbiol Immunol. 2003;276:125-44
pubmed: 12797446
Clin Cancer Res. 2020 Jul 1;26(13):3091-3099
pubmed: 32071116
J Virol. 2009 Jun;83(11):5567-73
pubmed: 19279092
J Immunol. 2000 Sep 1;165(5):2850-8
pubmed: 10946318
Nat Commun. 2017 May 26;8:15327
pubmed: 28548102
Clin Cancer Res. 2019 Aug 15;25(16):5061-5068
pubmed: 31113840
Trends Cancer. 2020 Jul;6(7):605-618
pubmed: 32610070
Br J Cancer. 2017 Aug 8;117(4):451-460
pubmed: 28704840